For example, autoantibodies against ADAMTS13, which regulates von Willebrand factor11, can impair its normal functions, thereby increasing thrombotic risk as seen in COVID-19 patients who exhibit a higher prevalence of ADAMTS13 antibodies and markedly reduced ADAMTS13 activity compared to healthy individuals12. This evidence concerns the gene ADAMTS13 and COVID-19.